High-Dose Melphalan, Etoposide ± Carboplatin (Mec) Combined with 12-Gray Fractionated Total-Body Irradiation in Children with Generalized Solid Tumors
Long-term disease-free survival is poor in patients with primary generalized or relapsed solid tumors. High-dose chemoradiotherapy with stem cell rescue improved survival, but more effective protocols are needed. From January 1988 to November 1988, we treated 7 patients (median age, 9 years; range,...
Gespeichert in:
| Veröffentlicht in: | Pediatric hematology and oncology 1991, Vol.8 (1), p.13-22 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 22 |
|---|---|
| container_issue | 1 |
| container_start_page | 13 |
| container_title | Pediatric hematology and oncology |
| container_volume | 8 |
| creator | Emminger, W. Emminger-Schmidmeier, W. Hawliczek, R. Peters, C. Höcker, P. Gadner, H. |
| description | Long-term disease-free survival is poor in patients with primary generalized or relapsed solid tumors. High-dose chemoradiotherapy with stem cell rescue improved survival, but more effective protocols are needed. From January 1988 to November 1988, we treated 7 patients (median age, 9 years; range, 3-23years) with an intensified treatment program. They received 12-Gy fractionated, total-body irradiation (FTBI). High-dose chemotherapy (MEC) consisted of melphalan (120-140 mg/m2 Mel) and eloposide (40-60 mg/kg VP-16) with or without carboplatin (1.5 g/m2 CBDCA). Although we combined 12-Gy FTBI with Mel, VP-16, ± CBDCA in doses used previously for high-dose single-agent chemotherapy, the extramedullary toxicity of FTBI with ME(C) was tolerable. Two of the four patients who were grafted without delay after good initial chemotherapy response are still alive in continued complete remission 30 and 33 months, respectively, after initial diagnosis. Early application of FTBI and ME(C) during first chemotherapy response might improve outcome in patients with primarily generalized solid tumors. |
| doi_str_mv | 10.3109/08880019109033423 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_19844324</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2029464</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-3a866b7d596c140f6255ff0a11d9554b410d1d147061d06f451c869a9fe8c8ff3</originalsourceid><addsrcrecordid>eNp9kN9qFDEchYModVt9AC-E3AgWOjWZZLIZ9Ean7bbQ4oX1evhN_jgpmWRIZinri_gcvoJP5iy7KkXoVQLf-Q7JQegVJaeMkvodkVISQuv5ThjjJXuCFrQqaUGEqJ-ixZYXc0A-R4c53xFCSrYsD9BBScqaC75APy7dt744i9ngG-PHHjyEE3w-xTFmpw3-9RM3kLo4ephcwG9vjDrGTRw6F4zG927qMS2LVYINvkigJhcDTDO5jRP44lPUG3yVEmgHW4TniqZ3XicTdvLKBJPAu--z8yV6N5vrIab8Aj2z4LN5uT-P0NeL89vmsrj-vLpqPl4XijM6FQykEN1SV7VQlBMryqqylgCluq4q3nFKNNWUL4mgmgjLK6qkqKG2RippLTtCdNerUsw5GduOyQ2QNi0l7Xbj9r-NZ-f1zhnX3WD0X2M_6szf7DlkBd4mCMrlf8W15JyV29yHXc4FG9MA9zF53U6w8TH9kdhjz3j_QO8N-KlXkEx7F9cpzLM98onfuHCp1g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>High-Dose Melphalan, Etoposide ± Carboplatin (Mec) Combined with 12-Gray Fractionated Total-Body Irradiation in Children with Generalized Solid Tumors</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Emminger, W. ; Emminger-Schmidmeier, W. ; Hawliczek, R. ; Peters, C. ; Höcker, P. ; Gadner, H.</creator><creatorcontrib>Emminger, W. ; Emminger-Schmidmeier, W. ; Hawliczek, R. ; Peters, C. ; Höcker, P. ; Gadner, H.</creatorcontrib><description>Long-term disease-free survival is poor in patients with primary generalized or relapsed solid tumors. High-dose chemoradiotherapy with stem cell rescue improved survival, but more effective protocols are needed. From January 1988 to November 1988, we treated 7 patients (median age, 9 years; range, 3-23years) with an intensified treatment program. They received 12-Gy fractionated, total-body irradiation (FTBI). High-dose chemotherapy (MEC) consisted of melphalan (120-140 mg/m2 Mel) and eloposide (40-60 mg/kg VP-16) with or without carboplatin (1.5 g/m2 CBDCA). Although we combined 12-Gy FTBI with Mel, VP-16, ± CBDCA in doses used previously for high-dose single-agent chemotherapy, the extramedullary toxicity of FTBI with ME(C) was tolerable. Two of the four patients who were grafted without delay after good initial chemotherapy response are still alive in continued complete remission 30 and 33 months, respectively, after initial diagnosis. Early application of FTBI and ME(C) during first chemotherapy response might improve outcome in patients with primarily generalized solid tumors.</description><identifier>ISSN: 0888-0018</identifier><identifier>EISSN: 1521-0669</identifier><identifier>DOI: 10.3109/08880019109033423</identifier><identifier>PMID: 2029464</identifier><identifier>CODEN: PHONEN</identifier><language>eng</language><publisher>Philadelphia, PA: Informa UK Ltd</publisher><subject>Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carboplatin - administration & dosage ; Child ; Combined Modality Therapy ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Etoposide - administration & dosage ; generalized solid tumors in children ; Hematopoiesis ; high-dose chemotherapy ; Humans ; intensified conditioning regimen (MEC) ; Medical sciences ; Melphalan - administration & dosage ; Neoplasms - blood ; Neoplasms - therapy ; Pharmacology. Drug treatments ; Whole-Body Irradiation</subject><ispartof>Pediatric hematology and oncology, 1991, Vol.8 (1), p.13-22</ispartof><rights>1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1991</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-3a866b7d596c140f6255ff0a11d9554b410d1d147061d06f451c869a9fe8c8ff3</citedby><cites>FETCH-LOGICAL-c431t-3a866b7d596c140f6255ff0a11d9554b410d1d147061d06f451c869a9fe8c8ff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/08880019109033423$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/08880019109033423$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,776,780,4010,27900,27901,27902,59620,59726,60409,60515,61194,61229,61375,61410</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19844324$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2029464$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Emminger, W.</creatorcontrib><creatorcontrib>Emminger-Schmidmeier, W.</creatorcontrib><creatorcontrib>Hawliczek, R.</creatorcontrib><creatorcontrib>Peters, C.</creatorcontrib><creatorcontrib>Höcker, P.</creatorcontrib><creatorcontrib>Gadner, H.</creatorcontrib><title>High-Dose Melphalan, Etoposide ± Carboplatin (Mec) Combined with 12-Gray Fractionated Total-Body Irradiation in Children with Generalized Solid Tumors</title><title>Pediatric hematology and oncology</title><addtitle>Pediatr Hematol Oncol</addtitle><description>Long-term disease-free survival is poor in patients with primary generalized or relapsed solid tumors. High-dose chemoradiotherapy with stem cell rescue improved survival, but more effective protocols are needed. From January 1988 to November 1988, we treated 7 patients (median age, 9 years; range, 3-23years) with an intensified treatment program. They received 12-Gy fractionated, total-body irradiation (FTBI). High-dose chemotherapy (MEC) consisted of melphalan (120-140 mg/m2 Mel) and eloposide (40-60 mg/kg VP-16) with or without carboplatin (1.5 g/m2 CBDCA). Although we combined 12-Gy FTBI with Mel, VP-16, ± CBDCA in doses used previously for high-dose single-agent chemotherapy, the extramedullary toxicity of FTBI with ME(C) was tolerable. Two of the four patients who were grafted without delay after good initial chemotherapy response are still alive in continued complete remission 30 and 33 months, respectively, after initial diagnosis. Early application of FTBI and ME(C) during first chemotherapy response might improve outcome in patients with primarily generalized solid tumors.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carboplatin - administration & dosage</subject><subject>Child</subject><subject>Combined Modality Therapy</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Etoposide - administration & dosage</subject><subject>generalized solid tumors in children</subject><subject>Hematopoiesis</subject><subject>high-dose chemotherapy</subject><subject>Humans</subject><subject>intensified conditioning regimen (MEC)</subject><subject>Medical sciences</subject><subject>Melphalan - administration & dosage</subject><subject>Neoplasms - blood</subject><subject>Neoplasms - therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Whole-Body Irradiation</subject><issn>0888-0018</issn><issn>1521-0669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kN9qFDEchYModVt9AC-E3AgWOjWZZLIZ9Ean7bbQ4oX1evhN_jgpmWRIZinri_gcvoJP5iy7KkXoVQLf-Q7JQegVJaeMkvodkVISQuv5ThjjJXuCFrQqaUGEqJ-ixZYXc0A-R4c53xFCSrYsD9BBScqaC75APy7dt744i9ngG-PHHjyEE3w-xTFmpw3-9RM3kLo4ephcwG9vjDrGTRw6F4zG927qMS2LVYINvkigJhcDTDO5jRP44lPUG3yVEmgHW4TniqZ3XicTdvLKBJPAu--z8yV6N5vrIab8Aj2z4LN5uT-P0NeL89vmsrj-vLpqPl4XijM6FQykEN1SV7VQlBMryqqylgCluq4q3nFKNNWUL4mgmgjLK6qkqKG2RippLTtCdNerUsw5GduOyQ2QNi0l7Xbj9r-NZ-f1zhnX3WD0X2M_6szf7DlkBd4mCMrlf8W15JyV29yHXc4FG9MA9zF53U6w8TH9kdhjz3j_QO8N-KlXkEx7F9cpzLM98onfuHCp1g</recordid><startdate>1991</startdate><enddate>1991</enddate><creator>Emminger, W.</creator><creator>Emminger-Schmidmeier, W.</creator><creator>Hawliczek, R.</creator><creator>Peters, C.</creator><creator>Höcker, P.</creator><creator>Gadner, H.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1991</creationdate><title>High-Dose Melphalan, Etoposide ± Carboplatin (Mec) Combined with 12-Gray Fractionated Total-Body Irradiation in Children with Generalized Solid Tumors</title><author>Emminger, W. ; Emminger-Schmidmeier, W. ; Hawliczek, R. ; Peters, C. ; Höcker, P. ; Gadner, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-3a866b7d596c140f6255ff0a11d9554b410d1d147061d06f451c869a9fe8c8ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carboplatin - administration & dosage</topic><topic>Child</topic><topic>Combined Modality Therapy</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Etoposide - administration & dosage</topic><topic>generalized solid tumors in children</topic><topic>Hematopoiesis</topic><topic>high-dose chemotherapy</topic><topic>Humans</topic><topic>intensified conditioning regimen (MEC)</topic><topic>Medical sciences</topic><topic>Melphalan - administration & dosage</topic><topic>Neoplasms - blood</topic><topic>Neoplasms - therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Whole-Body Irradiation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Emminger, W.</creatorcontrib><creatorcontrib>Emminger-Schmidmeier, W.</creatorcontrib><creatorcontrib>Hawliczek, R.</creatorcontrib><creatorcontrib>Peters, C.</creatorcontrib><creatorcontrib>Höcker, P.</creatorcontrib><creatorcontrib>Gadner, H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pediatric hematology and oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Emminger, W.</au><au>Emminger-Schmidmeier, W.</au><au>Hawliczek, R.</au><au>Peters, C.</au><au>Höcker, P.</au><au>Gadner, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-Dose Melphalan, Etoposide ± Carboplatin (Mec) Combined with 12-Gray Fractionated Total-Body Irradiation in Children with Generalized Solid Tumors</atitle><jtitle>Pediatric hematology and oncology</jtitle><addtitle>Pediatr Hematol Oncol</addtitle><date>1991</date><risdate>1991</risdate><volume>8</volume><issue>1</issue><spage>13</spage><epage>22</epage><pages>13-22</pages><issn>0888-0018</issn><eissn>1521-0669</eissn><coden>PHONEN</coden><abstract>Long-term disease-free survival is poor in patients with primary generalized or relapsed solid tumors. High-dose chemoradiotherapy with stem cell rescue improved survival, but more effective protocols are needed. From January 1988 to November 1988, we treated 7 patients (median age, 9 years; range, 3-23years) with an intensified treatment program. They received 12-Gy fractionated, total-body irradiation (FTBI). High-dose chemotherapy (MEC) consisted of melphalan (120-140 mg/m2 Mel) and eloposide (40-60 mg/kg VP-16) with or without carboplatin (1.5 g/m2 CBDCA). Although we combined 12-Gy FTBI with Mel, VP-16, ± CBDCA in doses used previously for high-dose single-agent chemotherapy, the extramedullary toxicity of FTBI with ME(C) was tolerable. Two of the four patients who were grafted without delay after good initial chemotherapy response are still alive in continued complete remission 30 and 33 months, respectively, after initial diagnosis. Early application of FTBI and ME(C) during first chemotherapy response might improve outcome in patients with primarily generalized solid tumors.</abstract><cop>Philadelphia, PA</cop><pub>Informa UK Ltd</pub><pmid>2029464</pmid><doi>10.3109/08880019109033423</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0888-0018 |
| ispartof | Pediatric hematology and oncology, 1991, Vol.8 (1), p.13-22 |
| issn | 0888-0018 1521-0669 |
| language | eng |
| recordid | cdi_pascalfrancis_primary_19844324 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carboplatin - administration & dosage Child Combined Modality Therapy Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Etoposide - administration & dosage generalized solid tumors in children Hematopoiesis high-dose chemotherapy Humans intensified conditioning regimen (MEC) Medical sciences Melphalan - administration & dosage Neoplasms - blood Neoplasms - therapy Pharmacology. Drug treatments Whole-Body Irradiation |
| title | High-Dose Melphalan, Etoposide ± Carboplatin (Mec) Combined with 12-Gray Fractionated Total-Body Irradiation in Children with Generalized Solid Tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T19%3A32%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-Dose%20Melphalan,%20Etoposide%20%C2%B1%20Carboplatin%20(Mec)%20Combined%20with%2012-Gray%20Fractionated%20Total-Body%20Irradiation%20in%20Children%20with%20Generalized%20Solid%20Tumors&rft.jtitle=Pediatric%20hematology%20and%20oncology&rft.au=Emminger,%20W.&rft.date=1991&rft.volume=8&rft.issue=1&rft.spage=13&rft.epage=22&rft.pages=13-22&rft.issn=0888-0018&rft.eissn=1521-0669&rft.coden=PHONEN&rft_id=info:doi/10.3109/08880019109033423&rft_dat=%3Cpubmed_pasca%3E2029464%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2029464&rfr_iscdi=true |